Journal of Cardiac Failure
Volume 14, Issue 8 , Pages 651-658 , October 2008

The Cost of Medical Management in Advanced Heart Failure During the Final Two Years of Life

Received 14 March 2008 ,Revised 27 May 2008 ,Accepted 2 June 2008.

References 

  1. American Heart Association. Heart disease and stroke statistics—2005 update. Dallas, TX: American Heart Association; 2005;
  2. Stevenson LW, Miller LW, Desvigne-Nickens P, et al. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH. Circulation. 2004;110:975–981
  3. American Heart Association. New heart failure guidelines stress early diagnosis and treatment. Available at: http://www.americanheart.org/presenter.jhtml?identifier=3032954. Accessed October 5, 2006.
  4. O'Connell JB, Bristow M. The economic impact of heart failure in the United States time for a different approach. J Heart Lung Transplant. 1994;13:S107–S112
  5. Masoudi FA, Baillie CA, Wang Y, et al. Complexity and cost of multi-drug regimens of older patients hospitalized for heart failure. Arch Intern Med. 2005;165:2069–2075
  6. Mackowiak J. Cost of heart failure to the healthcare system. Am J Manag Care. 1998;4:S338–S342
  7. Liu P, Arnold JM, Belenkie I, et al. The 2002/3 Canadian Cardiovascular Society consensus guideline update for the diagnosis and management of heart failure. Can J Cardiol. 2003;31(19):347–356
  8. O'Connell JB. The economic burden of heart failure. Clin Cardiol. 2000;23:III6–III10
  9. Rose EA, Gelijns AC, Moskowitz AJ, et al. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med. 2001;345:1435–1443
  10. Hunt SA, Baker DW, Chin MH, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure); International Society for Heart and Lung Transplantation; Heart Failure Society of America. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2001;104:2996–3007
  11. Cuzick J. A Wilcoxon-type test for trend. Stat Med. 1985;4:87–90
  12. In:  Wennberg JE,  Cooper MM editor. Dartmouth Atlas of Healthcare 1998. Chicago: American Health Association Press; 1988;
  13. Chang S, Long SR, Kutikova L, Bowman L, Crown WH, Lyman GH. Burden of pancreatic cancer and disease progression: economic analysis in the US. Oncology. 2006;70:71–80
  14. Hjelmgren J, Ceberg J, Persson U, Alvegard TA. The cost of treating pancreatic cancer—a cohort study based on patients' records from four hospitals in Sweden. Acta Oncol. 2003;42:218–226
  15. Au DH, Udris EM, Fihn SD, McDonell MB, Curtis JR. Differences in health care utilization at the end of life among patients with chronic obstructive pulmonary disease and patients with lung cancer. Arch Intern Med. 2006;166:326–331
  16. Shen AYJ, Wang XZ, Doris J, Moore N. Proportion of patients in a congestive heart failure care management program meeting criteria for cardiac resynchronization therapy. Am J Cardiol. 2004;94:673–676# Gupta SN, Jose VJ, Chandy ST. Heart failure: what proportion of patients satisfy the electrocardiographic criteria for cardiac resynchronization therapy?. Indian Heart J. 2003;55:619–623[Medline]# Guyomar Y, Houchaymi Z, Graux P, Heuls S, Rihani R, Cornaert P, et al. Indications for multisite pacing in patients with heart failure. Am J Cardiol. 2001;88:688–690[CrossRef][ISI][Medline]# Farwell D, Patel NR, Hall A, Ralph S, Sulke AN. How many people with heart failure are appropriate for biventricular resynchronization?. Eur Heart J. 2000;21:1246–1250[Abstract/Free Full Text]# De Sutter J, De Bondt P, Van de Wiele C, Fonteyne W, Dierckx R, Clement D, et al. Prevalence of potential candidates for biventricular pacing among patients with known coronary artery disease: a prospective registry from a single center. Pacing Clin Electrophysiol. 2000;23:1718–1721[ISI][Medline]# Werling C, Weisse U, Siemon G, Kiessling AH, Rameken M, Schwacke H, et al. Biventricular pacing in patients with ICD: how many patients are possible candidates?. Thorac Cardiovasc Surg. 2002;50:67–70[CrossRef][ISI][Medline]# Grimm W, Sharkova J, Funck R, Maisch B. How many patients with dilated cardiomyopathy may potentially benefit from cardiac resynchronization therapy?. Pacing Clin Electrophysiol. 2003;26:155–157[CrossRef][ISI][Medline]# Pedone C, Grigioni F, Boriani G, Lafiego C, Vassallo PL, Potena L, et al. Implications of cardiac resynchronization therapy and prophylactic defibrillator implantation among patients eligible for heart transplantation. Am J Cardiol. 2004;93:371–373[CrossRef][ISI][Medline]
  17. Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. JAMA. 2002;6(287):628–640
  18. Willerson JT, Kereiakes DJ. Cardiac resynchronization therapy: helpful now in selected patients with CHF. Circulation. 2004;109:308–309
  19. Jauhar S, Slotwiner DJ. The economics of ICDs. N Engl J Med. 2004;351:2542–2544
  20. Wachter RM, Luce JM, Hearst N, Lo B. Decisions about resuscitation: inequities among patients with different diseases but similar prognoses. Ann Intern Med. 1989;111:525–532
  21. Levenson JW, McCarthy EP, Lynn J, Davis RB, Phillips RS. The last six months of life for patients with congestive heart failure. J Am Geriatr Soc. 2000;48:S101–S109
  22. Lynn J, Teno JM, Phillips RS, et al. Perceptions by family members of the dying experience of older and seriously ill patients. Ann Intern Med. 1997;126:97–106
  23. Goldstein NE, Lynn J. Trajectory of end-stage heart failure: the influence of technology and implications for policy change. Perspect Biol Med. 2006;49:10–18
  24. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112:e154–e235
  25. Emanuel EJ. Cost savings at the end of life: what do the data show?. JAMA. 1996;275:1907–1914
  26. Payne SK. The health economics of palliative care. Oncology. 2002;16:801–812
  27. Lewina SN, Buttina BM, Powella MA, et al. Resource utilization for ovarian cancer patients at the end of life: how much is too much?. Gynecol Oncol. 2005;99:261–266
  28. Morris JN, Sherwood S, Wright SM, Gutkin CE. The last weeks of life: does hospice care make a difference?. In:  Mor V,  Greer DS,  Kastenbaum R editor. The hospice experiment. Baltimore: John Hopkins Press; 1988;p. 109–132
  29. Wallston KA, Burger C, Smith RA, Baugher RJ. Comparing the quality of death for hospice and nonhospice cancer patients. Med Care. 1988;26:177–182
  30. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2006;21(113):1424–1433
  31. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003;19(290):2581–2587
  32. Senni M, Santilli G, Parrella P, et al. A novel prognostic index to determine the impact of cardiac conditions and co-morbidities on one-year outcome in patients with heart failure. Am J Cardiol. 2006;15(98):1076–1082
  33. GC Friesinger J, Butler J. End-of-life care for elderly patients with heart failure. Clin Geriatr Med. 2000;16:663–675
  34. Wachter RM, Luce JM, Hearst N, Lo B. Decisions about resuscitation: inequities among patients with different diseases but similar prognoses. Ann Intern Med. 1989;111:525–532

 Presented at the 2006 American Heart Association Scientific Sessions, November 12 to 15, 2006, Chicago, Illinois.

 The REMATCH trial was supported, in part, by a cooperative agreement (HL-53986) funded by the National Heart Lung and Blood Institute of the National Institutes of Health, Bethesda, Maryland, and Thoratec Corporation, Pleasanton, California. Additional funding for the routine costs of clinical care associated with the trial was made available by the Center for Medicare and Medicaid Services and by the participating clinical centers. Reprint requests: Mark J. Russo, MD, MS, New York-Presbyterian Hospital/Columbia, Milstein Hospital Bldg, Room 7-435 GN, 177 Fort Washington Avenue, New York, NY 10032.

PII: S1071-9164(08)00180-2

doi: 10.1016/j.cardfail.2008.06.005

Journal of Cardiac Failure
Volume 14, Issue 8 , Pages 651-658 , October 2008

Article Tools

* Image Usage & Resolution